The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma

Horwitz, S.S.HorwitzO’Connor, O.A.O.A.O’ConnorPro, B.B.ProTrümper, L.L.TrümperIyer, S.S.IyerAdvani, R.R.AdvaniBartlett, N.L.N.L.BartlettChristensen, J.H.J.H.ChristensenMorschhauser, F.F.MorschhauserDomingo-Domenech, E.E.Domingo-DomenechIllidge, T.T.Illidge2022-04-012022-04-012022https://resolver.sub.uni-goettingen.de/purl?gro-2/105575enhttps://www.elsevier.com/tdm/userlicense/1.0/The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphomajournal_article10.1016/j.annonc.2021.12.002S0923753421048754